The stock of Organon & Co. (NYSE:OGN) last traded at $13.30, up 1.45% from the previous session.
OGN stock price is now -25.76% away from the 50-day moving average and -39.23% away from the 200-day moving average. The market capitalization of the company currently stands at $3.40B.
With the price target reduced from $33 to $16, Goldman Downgraded its rating from Buy to Neutral for Organon & Co. (NYSE: OGN).
Insiders disposed of 94,715 shares of company stock worth roughly $1.26 million over the past 1 year. A total of 0.11% of the company’s stock is owned by insiders.
With an opening price of $13.28 on Friday morning, Organon & Co. (NYSE: OGN) set off the trading day. During the past 12 months, Organon & Co. has had a low of $12.65 and a high of $32.43. The fifty day moving average price for OGN is $17.75 and a two-hundred day moving average price translates $21.79 for the stock.
The latest earnings results from Organon & Co. (NYSE: OGN) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.31, beating analysts’ expectations of $1.01 by 0.3. This compares to $0.92 EPS in the same period last year. The company reported revenue of $1.61 billion for the quarter, compared to $1.58 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.45 percent. For the current quarter, analysts expect OGN to generate $1.58B in revenue.
Organon & Co.(OGN) Company Profile
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
